BiomX Subsidiary Zorronet Receives Approximately $300,000 Purchase Order to Build Unified Operational Environment at Defense Technology Test and Evaluation Site
Rhea-AI Summary
BiomX (NYSE American: PHGE) reported that its subsidiary Zorronet received an approximately $300,000 purchase order to plan, integrate and deploy a unified operational environment at a defense technology test and evaluation site.
Zorronet will design communications, computing and control infrastructure, integrate multiple systems and deploy a dedicated command-and-control center, managing the project from initial characterization through operational handover. According to BiomX, this site-level deployment is a strategically important reference in complex defense testing environments and may support a repeatable offering for additional facilities in Israel and abroad. The customer’s identity and site details are not disclosed for confidentiality reasons.
Positive
- ~$300,000 purchase order for unified operational environment at defense test site
- End-to-end project scope from planning through integration, commissioning and handover
- Strategic reference deployment in a complex, sensitive defense testing environment
- Expands Zorronet’s presence in defense technology test and evaluation environments
- Demonstrates full-site solution capability combining software, infrastructure and systems integration
- Potentially repeatable offering for additional Israeli and international test facilities
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 05 | Acquisition announcement | Positive | -1.6% | BiomX acquired a 10% Motomea stake and obtained an option to acquire control. |
| Jul 28 | Acquisition terms | Positive | -7.1% | Zorronet acquisition obligations were restructured with extended payment timing. |
| Jul 24 | European collaborations | Positive | -4.7% | Zorronet announced collaborations targeting infrastructure, agriculture, monitoring and protection applications. |
| Jul 10 | Data center transition | Positive | -17.1% | Zorronet completed migration of core operations to a new advanced data center. |
| Jul 08 | Acquisition LOI | Positive | -8.4% | BiomX signed a non-binding LOI for a 60% Tsoock Defense Technologies stake. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
All five selected recent events had negative 24-hour price reactions.
Key Terms
command-and-control technical
systems integration technical
commissioning technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Strategic project expands Zorronet’s presence in defense technology test and evaluation environments and includes site infrastructure, systems integration, a dedicated command-and-control center and coordination with adjacent testing facilities
NETANYA, Israel, Aug. 14, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a company focused on defense, security and critical infrastructure technologies, today announced that its subsidiary, Zorronet Ltd. (“Zorronet”), has received an approximately
Under the project, Zorronet will design and establish the site’s communications, computing and control infrastructure, integrate multiple operational systems and deploy a dedicated command-and-control center. Zorronet will manage the project from initial characterization and planning through installation, integration, commissioning and operational handover.
The environment will bring together site security, safety, operations and testing activity within a unified operational picture. It will also support coordination with adjacent test facilities, enabling teams to manage activity across multiple areas while maintaining a shared view of operational conditions at the site and in its surrounding environment.
Zorronet’s command-and-control platform will consolidate information generated across the site’s systems and make it available within a centralized operational environment, supporting real-time coordination, operational oversight, post-activity review and informed decision-making. The project combines Zorronet’s software platform with communications and computing infrastructure, systems integration and control-room deployment, reflecting the Company’s ability to deliver a complete operational environment rather than a standalone software solution.
The order follows additional sites previously delivered by Zorronet and was awarded after the customer evaluated both the Company’s technology and its ability to manage and execute a complete project from initial characterization and planning through integration, deployment and site delivery. BiomX believes the project represents a strategically important reference deployment for Zorronet in a complex and sensitive operating environment.
The project also establishes an initial foothold for Zorronet in defense technology test and evaluation environments, where safety, security, testing activity and site operations must be coordinated across multiple systems, teams and locations. BiomX believes that the capabilities being deployed through this project can form the basis for a repeatable offering that may be applicable to additional test and evaluation facilities in Israel and internationally.
“This order is another indication that Zorronet is progressing in line with the business plan we have established for the company,” said Michael Oster, Chief Executive Officer of BiomX. “What is particularly important to us is the nature of the deployment: Zorronet is being entrusted with an end-to-end operational environment in a complex defense technology testing setting, following the customer’s evaluation of its capabilities in prior projects. With Roy Timor-Rousso recently joining BiomX as Chief Business Officer, we are also focused on translating deployments such as this into broader commercial opportunities across similar environments in Israel and international markets.”
The order further demonstrates Zorronet’s ability to extend its role beyond the deployment of its software platform by combining operational intelligence, command-and-control technology, infrastructure and systems integration into a complete site-level solution.
Due to the sensitive nature of the project and applicable confidentiality obligations, the identity of the customer, the precise location of the site and the nature of the defense-related testing activities are not being disclosed.
About BiomX Inc.
BiomX Inc. is a technology company focused on building a diversified platform across defense, security and critical infrastructure technologies. Through its subsidiaries and strategic initiatives, BiomX is pursuing technologies and capabilities designed to support operational intelligence, command-and-control, systems integration and coordinated management across mission-critical environments.
About Zorronet Ltd.
Zorronet Ltd., a BiomX company, develops AI-powered operational intelligence and command-and-control technology that connects cameras, sensors, drones, IoT devices and other field systems into a unified real-time operating picture. The platform enables organizations to bring together information, operational workflows and communications across multiple systems and locations, supporting both centralized control rooms and distributed teams in the field.
Zorronet combines its software platform with systems integration, communications infrastructure and operational deployment capabilities, enabling the Company to support projects from initial characterization and planning through implementation, commissioning and ongoing operations. Its technologies and capabilities are applicable across defense, homeland security, critical infrastructure, transportation, municipalities, agriculture, smart cities, test and evaluation environments, remote asset protection and civilian security applications.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by words such as "expects," "intends," "plans," "believes," "will," "may," "anticipates," "estimates" and similar expressions. These statements are based on the Company's current expectations and are subject to a number of risks and uncertainties, many of which are beyond the Company's control, that could cause actual results to differ materially from those expressed or implied.
These risks and uncertainties include, among others, Zorronet’s ability to successfully execute and complete the project described herein in accordance with the anticipated scope, schedule and customer requirements; the ability of Zorronet’s technology and systems integration capabilities to perform as expected in the test and evaluation environment; the potential for the project to serve as a reference deployment or lead to additional orders, projects or commercial opportunities; Zooronet’s ability to expand its presence in defense technology test and evaluation environments and other defense, security and mission-critical markets in Israel and internationally; the Company’s ability to execute its business plan for Zorronet and translate existing deployments into broader commercial opportunities; the adoption of Zorronet’s technologies by additional customers and markets; the risk that the Company may not regain compliance with the NYSE American continued listing standards within the plan period or at all; the risk that the Company may not make progress consistent with its plan; the possibility that the Company's common stock may be suspended from trading or delisted from the NYSE American; the Company's ability to raise additional capital and to execute its business and strategic initiatives; the Company's going concern qualification; and the other risks described in the Company's filings with the Securities and Exchange Commission, including under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC on February 19, 2026, as supplemented by the Form 10-K/A filed with the SEC on April 30, 2026, the Company's Current Report on Form 8-K filed with the SEC on May 5, 2026, and the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 filed with the SEC on May 20, 2026, as well as the Company's other filings with the SEC.
The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
Investor Relations Contact:
Yairo@biomx.com - IR & Communications Manager
